CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
癌症免疫治疗诱导自身免疫的抗炎策略
英文原题：Anti-inflammatory approaches in cancer immunotherapy-induced autoimmunity.
查看英文原题
Anti-inflammatory approaches in cancer immunotherapy-induced autoimmunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症免疫治疗，包括异基因造血细胞移植、CAR-T（CAR-T）细胞输注、双特异性抗体和免疫检查点抑制剂（ICIs），已经彻底改变了癌症的治疗。然而，治疗耐药和免疫介导的副作用降低了总体成功率。近期在2026年ATT会议上报告了这两个领域的新进展。使用转化生长因子（TGF）-激活激酶-1（TAK1）-NF-B-p38丝裂原活化蛋白激酶（MAPK）通路抑制治疗免疫效应细胞相关神经毒性综合征（ICANS）在临床前模型中被证明有效。TAK1抑制减少了小胶质细胞活化，并改善了CAR19 T细胞输注后的神经认知功能。本综述讨论了ICANS、移植物抗宿主病（GVHD）和ICI介导的副作用领域的新进展。
展开英文摘要原文
Cancer immunotherapy, including allogeneic haematopoietic cell transplantation, infusion of chimeric antigen receptor T (CAR-T) cells, bispecific antibodies, and immune checkpoint inhibitors (ICIs), has revolutionised the treatment of cancer.
However, therapy resistance and immune-mediated side effects reduce the overall success. Recent developments in these 2 areas were reported at the 2026 ATT conference. Treatment of immune effector cell-associated neurotoxicity syndrome (ICANS) using transforming growth factor (TGF )-activated kinase-1 (TAK1)-NF- B-p38 mitogen-activated protein kinase (MAPK) pathway inhibition was shown to be effective in preclinical models.
TAK1 inhibition reduced microglia activation and improved neurocognitive function after CAR19 T-cell transfer. This review discusses new developments in the fields of ICANS, graft-vs-host disease (GVHD), and ICI-mediated side effects.
论文信息
- 作者
- Zeiser R
- 单位
- Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.Germany
- 文献类型
- 综述
- 期刊
- EULAR rheumatology open2026 Sep
- 原文标识
- PubMed 42620644 · DOI 10.1016/j.ero.2026.100223
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →